Table 1.

Important clinical trials that reported checkpoint inhibitor pneumonitis (CIP) in NSCLC patients with PD-1/PD-L1 blockade.

Registration number	Published year	Treatment	Enrollment a	Phage	NSCLC stage	Incidence, n (%)		Reference
						Any grade	High grade (≥3)
PD-1 inhibitor
NCT01642004	2015	Nivolumab	131	III	IIIB or IV	6 (5.0)	1 (1.0)	(15)
NCT01673867	2015	Nivolumab	287	III	IIIB or IV	8 (2.8)	3 (1.0)	(16)
NCT02477826	2018	Nivolumab	391	III	IV	9(2.3)	6 (1.5)	(17)
NCT02477826	2018	Nivolumab + Ipilimumab	576	III	IV	22 (3.8)	13 (2.3)	(17)
NCT01295827	2015	Pembrolizumab	550	III	IIIB or IV	21 (3.8)	11 (2.0)	(18)
NCT01905657	2016	Pembrolizumab	682	II/III	IIIB or IV	26 (3.8)	12 (1.8)	(19)
NCT02142738	2016	Pembrolizumab	154	III	IIIB or IV	9 (5.8)	4 (2.6)	(20)
NCT02220894	2019	Pembrolizumab	636	III	IIIB or IV	53 (8.3)	22 (3.5)	(21)
NCT02775435	2018	Pembrolizumab + Carboplatin+ (Nab-) Paclitaxel	278	III	IV	18 (6.5)	7 (2.5)	(10)
NCT03088540	2021	Cemiplimab	355	III	IIIB, IIIC or IV	8 (2.3)b	2 (0.6)c	(22)
PD-L1 inhibitor
NCT02008227	2017	Atezolizumab	609	III	IIIB or IV	6 (1.0)	4 (0.7)	(4)
NCT02409342	2020	Atezolizumab	286	III	IV	11 (3.8)	2 (0.7)	(23)
NCT02657434	2021	Atezolizumab + Pemetrexed	291	III	IV	18 (6.2)	6 (2.1)	(24)
NCT02367781	2019	Atezolizumab + Carboplatin + Nab-paclitaxel	473	III	IV	25 (5.3)	2 (0.4)	(25)
NCT02125461	2017	Durvalumab	475	III	III	51 (10.7)	8 (1.7)	(26)
NCT02453282	2020	Durvalumab	369	III	IV	8 (2.2)	5 (1.4)	(27)
NCT02453282	2020	Durvalumab + Tremelimumab	371	III	IV	25 (6.7)	11 (3.0)	(27)

NSCLC, non-small-cell lung cancer; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.

^aPatients enrolled in and received ICI treatment.

^bIncludes 7 immune-related pneumonitis and 1 immune-mediated pneumonitis.

^cIncludes 1 immune-related pneumonitis and 1 immune-mediated pneumonitis.